RDI

Biotechnology & nanotechnology

Our R&D&I efforts are disruptive, merging cutting-edge biotechnology and nanotechnology to redefine precision medicine through intelligent delivery systems. We develop programmable nanostructures that transport bioactive compounds directly to the therapeutic target, minimizing side effects and maximizing biological efficacy in neurological and regenerative treatments.

By integrating nanoscale sensors with gut-brain axis science, we have created a predictive health platform that adjusts compound release in real time. This approach not only treats diseases with molecular precision but also sets new standards for human performance optimization and high-performance cosmetics, transforming biological complexity into scalable, personalized medical solutions.

CRO

Our operates under strict Good Clinical Practice (GCP) compliance, serving as a global hub for multicenter studies and high-impact scientific collaboration. We provide the regulatory and technical infrastructure necessary to validate breakthroughs across borders, ensuring that every discovery meets the highest international standards for safety, ethics, and data integrity.

Translational Team

Our translational team brings together diverse expertise in microbiology, neuroscience, integrative medicine, biotechnology, and nanotechnology. This multidisciplinary synergy allows us to bridge the gap between complex laboratory research and real-world clinical applications, transforming scientific insights into holistic and innovative healthcare solutions.

Validate models

Our validated models are built on a proven track record of bringing two breakthrough products from initial development to successful Go-To-Market (GTM) execution. We are now scaling this repeatable framework to ensure that every new innovation follows a predictable, high-performance path from clinical validation to global commercial availability.

Ai Diane

Our R&D&I efforts accelerate clinical validation by utilizing BERT-based architectures trained as digital twins of real patients. These neural networks simulate complex biological and behavioral responses based on extensive clinical datasets, enabling high-precision in silico testing before laboratory stages.

This disruptive approach significantly reduces development time and costs by predicting compound efficacy and safety with molecular accuracy. By integrating deep learning with dynamic simulations, we ensure that only the most promising innovations advance to human clinical trials.